Filgotinib
Ulcerative Colitis
Phase 3Active
Key Facts
About Gilead Sciences
Founded in 1987, Gilead Sciences has established itself as a premier biopharmaceutical company with a strong track record of bringing transformative medicines to market. The company generates substantial revenue from its portfolio of approved drugs, particularly in HIV and hepatitis, while investing heavily in R&D to advance next-generation therapies in oncology, inflammation, and infectious diseases. With a market capitalization of over $170 billion and a diversified pipeline, Gilead continues to be a major player in the global pharmaceutical landscape.
View full company profileOther Ulcerative Colitis Drugs
| Drug | Company | Phase |
|---|---|---|
| Mirikizumab | Eli Lilly | Phase 3 |
| Obefazimod (ABX464) | Abivax | Phase 3 |
| Icotrokinra (JNJ-2113) | Protagonist Therapeutics | Phase 3 |
| DE-130 (Etrasimod) | Rohto Pharmaceutical | Phase 3 |
| DE-122 (Carotegrast methyl) | Rohto Pharmaceutical | Phase 3 |
| Methylene Blue MMX® | Cosmo Pharmaceuticals | Preclinical |
| KRP-203 (Amiselimod) | Kissei Pharmaceutical | Phase II |
| EVO301 | Evommune | Phase 1 |
| Pentasa (Mesalazine) | Zeria Pharmaceutical | Approved/Commercial |
| SER-301 | Seres Therapeutics | Phase 1b |
| SER-287 | Seres Therapeutics | Phase 2b |
| IMP731 | Immutep | Phase 2 |